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PURPOSE. The purpose of this study was to determine the efficacy of suberoylanilide
hydroxamic acid (SAHA), a histone deacetylase inhibitor (HDACi), in prevention of excessive
wound healing and scar formation in a rabbit model of glaucoma filtration surgery (GFS).
METHODS. A rabbit model of GFS was used. Rabbits that underwent GFS received balanced salt
solution, or SAHA (50 lM), or mitomycin C (0.02%). Clinical scores of IOP, bleb vascularity,
and slit-lamp examination were performed. On postoperative day 14, rabbits were killed and
the bleb tissues were collected for evaluation of tissue fibrosis with hematoxylin and eosin,
Masson trichrome, a-smooth muscle actin (aSMA), and F-actin staining. Furthermore, SAHA-
mediated acetylation of histones in corneal fibroblasts and conjunctiva were determined by
Western blot analysis.
RESULTS. Suberoylanilide hydroxamic acid treatment after GFS showed no signs of edema,
corneal opacity, endophthalmitis, or cataract formation. Morphometric analysis of SAHA-
treated eyes showed higher bleb length (P < 0.001), bleb area (P < 0.05), lower IOP (P <
0.01), and decreased vascularity compared to control. Furthermore, SAHA treatment showed
significantly reduced levels of aSMA (P < 0.001), F-actin (P < 0.01), and collagen deposition
(P < 0.05) at the sclerotomy site. In addition, SAHA treatment increased the acetylation status
of H3 and H4 histones in corneal fibroblasts and conjunctiva.
CONCLUSIONS. This study demonstrates that HDAC inhibition is an attractive pharmacologic
target to modulate GFS wound healing, and SAHA, an HDACi, can be a useful adjunct to
improve the GFS outcome.
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Glaucoma is the second leading cause of blindnessaccording to the World Health Organization.1 In the
United States alone, glaucoma affects approximately 2.2 million
people.2 The major goal of glaucoma therapy is to reduce IOP
to levels considered safe for the optic nerve to preserve visual
function. Currently, several topical drugs capable of reducing
intraocular pressure are used for glaucoma treatment.3 How-
ever, a large number of patients do not respond adequately to
topical drug therapy to reduce IOP. The most preferred
treatment for such patients is glaucoma filtration surgery
(GFS). A major deterrent to the success of GFS is caused by
aberrant postoperative wound healing resulting in excessive
extracellular matrix (ECM) synthesis, which leads to fibrosis
over filtering bleb.4–7 Development of fibrosis and collagen
deposit at the sclerotomy site compromises bleb’s proper
functioning and disables its ability to maintain nonpathologic
reduced IOP. To prevent this common complication, cytotoxic
drugs such as mitomycin C (MMC) and 5-fluorouracil are
frequently utilized intraoperatively and in clinical practice to
reduce scar formation caused by GFS.8–10 Though these drugs
are effective in preventing ocular fibrosis and improving the
outcome of filtration surgery, they are known to cause sight-
threatening complications, including widespread cell death,
bleb leak, hypotony, and/or endophthalmitis.11–15 Thus, drugs
that do not cause intense wound healing and can effectively
prevent bleb fibrosis without significant side effects are needed
for glaucoma management.
Glaucoma filtration surgery initiates a cascade of events
including blood exudation, fibrin deposit, recruitment of
inflammatory cells, and release of cytokines/growth fac-
tors.4–7,16,17 The released cytokines alter the gene expression
of proliferative, cytoskeletal, and matrix proteins, thus leading
to fibrosis.18 Epigenetic regulations play a critical role, which
comprises regulation of gene expression by methylation/
acetylation of DNA and histone proteins. Histone acetylation
regulates gene expression by altering DNA structure, thus
influencing DNA binding to various transcription factors.19,20
Histone deacetylase inhibitors (HDACis) represent a new class
of pharmacologic agents that can modulate gene expression by
increasing histone acetylation. Histone deacetylase inhibitors
are shown to have pleiotropic antifibrotic effect in vivo in a
wide variety of animal models of skin, liver, lung, and heart
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fibrosis.21–28 Although several HDACis are at various stages of
preclinical and clinical development, suberoylanilide hydroxa-
mic acid (SAHA) (vorinostat) is the only HDACi currently
approved by the U.S. Food and Drug Administration (FDA) for
use in human patients. We recently demonstrated the
antifibrotic effect of SAHA on laser surgery–induced corneal
scaring in vivo.29,30 Unlike other antifibrotic agents, SAHA is
relatively nontoxic and does not affect the viability or
proliferation of corneal fibroblasts.29–32 Given the potent
antifibrotic effect of SAHA and its relative lack of toxicity to
normal cells, we hypothesized that SAHA may represent a
prospective therapeutic agent to attenuate postoperative
fibrosis after filtration surgery. Therefore, the present study
was designed to test the antifibrotic efficacy of SAHA (FDA-
approved HDACi) in a rabbit model of GFS.
MATERIALS AND METHODS
Glaucoma Filtration Surgery in Rabbits
Female New Zealand white rabbits were used in the study. The
Institutional Animal Care and Use Committee (ACUC) of the
University of Missouri-Columbia and Harry S. Truman Memorial
Veterans’ Hospital approved the study. All animals were treated
in accordance with the ARVO Statement for the Use of Animals
in Ophthalmic and Vision Research. The rabbits were
anesthetized by intramuscular injection of a mixture of
ketamine hydrochloride (50 mg/kg) and xylazine hydrochlo-
ride (10 mg/kg). In addition, topical ophthalmic 0.5%
proparacaine hydrochloride (Alcon, Fort Worth, TX, USA)
was used for local anesthesia. A partial-thickness corneal
traction suture (6-0 silk) was placed in the superior cornea to
rotate the eye inferiorly. A superior fornix-based conjunctival
flap was created. The anterior chamber was entered using a
Beaver blade, and a 1.531.5 mm full-thickness sclerotome was
created using the blade. A peripheral iridectomy was
performed. The conjunctival incision was closed with 10-0
nylon suture. Neomycin, polymyxin B sulfates, bacitracin zinc,
and hydrocortisone ointment was applied at the end of the
surgery and then once daily for 1 week after the surgery.
Preparation of SAHA Solution and Treatment
Regimen
A 10-mM stock solution of SAHA (Cayman Chemical Company,
Ann Arbor, MI, USA) was prepared by dissolving in dimethyl
sulfoxide (DMSO) and then further diluted to 50 lM with
balanced salt solution (BSS) eye drops (Alcon). For vehicle
control, the same volume of DMSO was diluted with BSS. The
0.04% MMC stock solution was prepared in BSS and a 0.02%
final dose of MMC was given to rabbits. The rabbits were divided
into three treatment groups. Group I rabbits received 100 lL
subconjunctival injection of vehicle 30 minutes before the GFS
surgery, and group II rabbits received 100 lL subconjunctival
injection of 50 lM SAHA solution 30 minutes before GFS. Group
III rabbits were injected with 100 lL subconjunctival solution of
0.02% MMC 30 minutes before surgery.
Clinical Evaluation
Clinical evaluation was performed to check the IOP, general
appearance, and vascularity of the bleb. All these clinical
parameters were recorded before the surgery to obtain the
baseline values and on days 3, 5, 7, 10, and 14 after surgery. To
measure IOP, tonometry was performed using an applanation
tonometer (Tono-pen; Reichert Technologies, Depew, NY,
USA) with animals under topical anesthesia. Bleb size was
graded by measuring its width and length. Bleb vascularity was
graded as 0¼ avascular; 1¼ normal vascularity; 2¼hyperemic;
3 ¼ very hyperemic. Anterior chamber inflammation was
assessed by slit-lamp examination and graded 0 ¼ no
inflammation; 1 ¼ cells present; 2 ¼ fibrin formation; 3 ¼
hypopyon present.
Histologic Evaluation
On postoperative day 14, rabbits were humanely euthanized with
pentobarbital (150 mg/kg) under general anesthesia. The eyes
were enucleated together with the conjunctiva to preserve the
bleb and snap frozen in optimal cutting temperature fluid. The
tissues were sectioned and stained with hematoxylin and eosin
(H&E). Masson’s trichrome staining was performed to stain
collagen. Immunofluorescence staining for F-actin (a marker for
activated fibroblasts and myofibroblasts) was performed using
Alexa Fluor 594 conjugated phalloidin (1:40 dilution, A12381;
Invitrogen, Inc., Carlsbad, CA, USA). Immunofluorescence
staining for a-smooth muscle actin (aSMA), a marker for
myofibroblasts, was performed with mouse monoclonal primary
aSMA antibody (1:100 dilution, M0851; Dako, Carpinteria, CA,
USA). Tissue sections were incubated with 2% bovine serum
albumin for 30 minutes at room temperature and then with aSMA
monoclonal antibody for 90 minutes. For detection of the primary
antibody, the sections were exposed to Alexa 488 goat anti-mouse
IgG secondary antibody (1:500 dilution, A11001; Invitrogen, Inc.)
for 1 hour. The tissue sections at the site of sclerotomy and the
sections on every sixth tissue slide on the either side of the
sclerotomy were stained for F-actin andaSMA. Aftercompletion of
immunostaining, tissue sections were mounted in medium
containing DAPI (Vectashield; Vector Laboratories, Inc., Burlin-
game, CA, USA), viewed, and photographed under a fluorescence
microscope (Leica Microsystems, Deerfield, IL, USA) equipped
with a digital camera system (SpotCam RT KE; Diagnostic
Instruments, Inc., Sterling, MI, USA). The stained areas in the
imaged slides were quantified using Image J software (http://
imagej.nih.gov/ij/; provided in the public domain by the National
Institutes of Health, Bethesda, MD, USA).
Western Blot Analyses
Human corneal fibroblast cells were treated with or without
SAHA (2.5 lM) at different time intervals as indicated in figure
legends. Rabbits received a 100-lL subconjunctival injection of
50 lM SAHA. Cell lysates were prepared from human corneal
fibroblast cells treated with SAHA (2.5 lM) at 0, 2, 4, 6, 16, and
24 hours. Rabbit conjunctival tissues were harvested at 0, 2, 6,
and 24-hour time points. Cell and tissue lysates were analyzed
by Western blotting using anti-acetyl histone H3, anti-acetyl
histone H4 (Cell Signaling, Beverly, MA, USA), and b-actin
(Santa Cruz Biotechnology, Inc., Dallas, TX, USA) antibodies
respectively. All Western blots for each protein were used with
three rabbit tissues and repeated at least two times. Digital
quantification of Western blots was performed using Image J
software (National Institutes of Health, Bethesda, MD, USA)
and Image Studio software (Version 5.2, GraphPad Software,
Inc., La Jolla, CA, USA).
Statistical Analysis
The results are expressed as mean 6 SEM. The data for bleb
length, area, vascularity, and IOP were analyzed by 2-way
ANOVA and Bonferroni test using GraphPad Prism 6.0 (Graph-
Pad Software, Inc., La Jolla, CA, USA), and P < 0.05 was
considered to be statistically significant. The immunostaining
data were analyzed using a t-test.
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RESULTS
Clinical Evaluation
The subconjunctival injection of SAHA was well tolerated and
no signs of hyperemia or inflammation were detected at the
site of injection. No sign of corneal edema, corneal opacity,
endophthalmitis, or cataract were observed in any of the SAHA-
treated rabbits. On the contrary, MMC-treated rabbit eyes
showed corneal neovascularization and opacity (Figs. 1H, 1I).
Bleb Morphology and Characteristics
Biomicroscopy was performed on the rabbit eyes to monitor
bleb characteristics. Figure 1 shows the typical appearance of
blebs in no-treatment control (Figs. 1A–C), SAHA-treated (Figs.
1D–F), and MMC-treated (Figs. 1G–I) rabbits. Suberoylanilide
hydroxamic acid–treated rabbit eyes showed transparent and
elevated blebs (Figs. 1D–F) compared to flat and scarred blebs
in no-treatment control rabbits (Figs. 1A–C). The MMC-treated
rabbits also showed elevated blebs, but these blebs had a thin,
avascular, and cystic appearance (Figs. 1G–I).
The morphometric analysis of the bleb length and area was
performed using Vernier caliper and digital quantification of
the acquired images. Figure 2 shows the mean bleb length (Fig.
2A) and bleb area (Fig. 2B) in no-treatment control and SAHA-
and MMC-treated rabbits at day 3, day 7, and day 14 after GFS.
The SAHA-treated rabbit eyes showed significantly higher bleb
area (P < 0.05) and length (P < 0.001) compared to untreated
controls (Fig. 2). The MMC-treated rabbit eyes also showed
significantly higher bleb area (P < 0.01) and length (P < 0.001)
as compared to untreated controls. The relative comparison
between SAHA- and MMC-treated groups demonstrated that
MMC-treated rabbits had higher bleb area and length as
compared to SAHA-treated rabbits, but the difference was not
statistically significant.
Figure 3 shows vascularity scores of the blebs in no-
treatment control and SAHA-treated and MMC-treated rabbits.
The no-treatment control group showed increased vascularity
in response to the surgical trauma. Suberoylanilide hydroxamic
acid treatment significantly (P < 0.01) attenuated bleb
vascularity on day 7 and day 14 after GFS. Mitomycin C
treatment also caused a very robust decrease in bleb
vascularity, and the effect was significantly more as compared
to SAHA. By day 14, all the MMC-treated blebs were completely
avascular and had a cystic appearance.
Intraocular Pressure
Figure 4 shows the effect of SAHA and MMC treatment on IOP
in the rabbit eyes after GFS. As anticipated, there was a
significant (P < 0.01) decrease in IOP in the no-treatment
FIGURE 1. Suberoylanilide hydroxamic acid or MMC treatment improves bleb morphology after GFS. Representative stereomicroscopic images
captured at day 3, 7, and 14 after GFS showing bleb characteristics in no-treatment control (A–C) and SAHA-treated (D–F) and MMC-treated (G–I)
rabbit eyes. Suberoylanilide hydroxamic acid– or MMC-treated rabbit eyes showed bigger bleb area (outlined in black dotted lines). Scale bar: 3 mm.
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control and SAHA- and MMC-treated rabbits on day 3 after GFS
as compared to the preoperative baseline values indicating
successful surgery. However, by day 7 and day 14 the IOP
started to increase in the untreated control group. On the
contrary, SAHA- and MMC-treated rabbit showed lower IOP
compared to the no-treatment control eyes, but the results
were not statistically significant.
Histologic Evaluation
To evaluate whether SAHA treatment affected collagen
deposition and myofibroblast formation after GFS, histologic
staining and immunostaining were performed on the rabbit eye
tissue sections. The H&E staining of the eye tissues obtained
from no-treatment control rabbits (Fig. 5A) shows that the site
of sclerotomy is densely packed with fibrous tissue. On the
contrary, eye tissues of SAHA-treated rabbits (Fig. 5B) show
mild fibrous deposit and a loosely arranged conjunctival tissue.
Furthermore, Masson trichrome staining revealed fewer
collagen deposits at the site of sclerotomy in the SAHA-treated
(Fig. 5D) tissues as compared to the eye tissue sections
obtained from no-treatment control rabbits (Fig. 5C).
To determine the effect of SAHA treatment in acetylation
status of histones, we performed Western blot analyses using
human corneal fibroblast cells (Fig. 6A) and conjunctiva tissue
(Fig. 6B) treated with SAHA at different time intervals.
Suberoylanilide hydroxamic acid treatment increased the
acetylation status of histone H3 and H4 and attained maximum
at 6 hours and gradual decrease at 24 hours. Corresponding
Western blot quantitation data are provided in Figures 6C
through 6F. These data suggest that SAHA treatment effectively
increases the acetylation status of histone H3 and H4, thereby
regulating target gene expression or repression involved in
excessive wound healing and scar formation.
FIGURE 2. Quantitation of bleb area and length. Quantification of bleb
length (A) and bleb area (B) at day 3, 7, and 14 after glaucoma filtration
surgery in no-treatment control and SAHA- and MMC-treated rabbit
eyes. Suberoylanilide hydroxamic acid– or MMC-treated rabbits showed
significantly bigger blebs. r P < 0.05, s P < 0.01, W P < 0.001
compared to control. The Greek letter in P values indicate significance
levels.
FIGURE 3. Suberoylanilide hydroxamic acid decreases bleb vascularity.
Quantification of bleb vascularity at day 3, 7, and 14 after GFS in no-
treatment control and SAHA- and MMC-treated rabbit eyes. Both SAHA
and MMC significantly reduced the bleb vascularity. s P < 0.01
compared to control, W P < 0.001 compared to control and SAHA.
FIGURE 4. Suberoylanilide hydroxamic acid or MMC reduces IOP.
Intraocular pressure measured at day 3, 7, and 14 after glaucoma
filtration surgery in no-treatment control and SAHA- or MMC-treated
rabbits. Suberoylanilide hydroxamic acid– or MMC-treated rabbit had
lower IOP at day 7 and day 14 as compared to no-treatment control, but
the decrease is not statistically significant.
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FIGURE 5. Suberoylanilide hydroxamic acid decreases collagen deposition at the site of GFS. Representative images showing H&E (A, B) and
Masson’s trichrome (C, D) staining in no-treatment control (A, C) and SAHA-treated (B, D) rabbit eyes. The tissues were collected at day 14 after the
glaucoma filtration surgery. The H&E staining of SAHA-treated tissue sections (B) shows loosely arranged, less-fibrous conjunctival tissues, whereas
no-treatment control tissues (A) are densely packed with fibrous deposit. Masson’s trichrome staining shows prominent collagen deposit (blue
color) in control tissues (C), whereas collagen deposit is notably decreased in SAHA-treated rabbit tissues (D). Scale bar: 400 lm.
FIGURE 6. Suberoylanilide hydroxamic acid treatment increases acetylation of histones in human corneal fibroblasts and rabbit conjunctiva tissues.
(A) Human corneal fibroblast cells treated with SAHA (2.5 lM) for indicated times and (B) rabbit conjunctiva injected with SAHA (50 lM) for
indicated times were analyzed by Western blot using anti–Ac-histone H3, anti–Ac-histone H4, and anti–b-actin antibodies. Corresponding Western
blot quantitative analysis data provided in C, D, E and F panels.
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Presence of activated fibroblasts and myofibroblasts is a key
feature of scarred bleb. Therefore, immunostaining for F-actin
(a marker for activated fibroblasts and myofibroblasts) and
aSMA (a marker for myofibroblasts) was performed to detect
the changes in the pattern of these proteins.33 Ocular tissue
sections collected from no-treatment control rabbits showed
intense F-actin (Fig. 7A) and aSMA (Fig. 8A) staining at the site
of sclerostomy, in the subconjunctival space, and in the sclera.
On the other hand, ocular tissues collected from SAHA-treated
rabbit showed sparse F-actin (Fig. 7B) and aSMA (Fig. 8B)
staining at the site of sclerostomy, in the subconjunctival space,
and in the sclera. Morphometric quantification for F-actin and
aSMA revealed that SAHA treatment caused a significant
decrease in the F-actin–stained (Fig. 7D) and aSMA-stained
(Fig. 8D) area (P < 0.01), thus confirming that the improved
bleb characteristics in SAHA-treated rabbits is complemented
by a decreased fibrosis and scarring at the site of sclerostomy.
As expected, MMC treatment also caused a very robust
decrease in F-actin (Fig. 7C) and aSMA (Fig. 8C) staining. The
morphometric quantification revealed that the MMC effect was
significantly more as compared to SAHA. However, it should be
noted that MMC treatment was associated with notable toxicity
to the conjunctival epithelium. DAPI nuclear staining revealed
(Figs. 7–8) a continuous and uniform conjunctival epithelium
at the site of sclerostomy in no-treatment control and SAHA-
treated rabbit tissue sections. On the other hand, MMC-treated
rabbit tissue showed discontinuous and highly sparse DAPI
nuclear staining for the conjunctival epithelium, thus suggest-
ing a cytotoxic effect of MMC to the cells of conjunctival
epithelium.
DISCUSSION
Glaucoma filtration surgery remains the mainstay procedure
for the clinical management of drug-refractory glaucoma.
Postoperative wound healing of the scleral flap and scarring
of the overlying conjunctiva are the major impediments to
surgical success of GFS.4–7 In the present study, we demon-
strate that SAHA remarkably reduces postoperative scarring in
the rabbit model of GFS. Bleb areas were consistently larger in
the SAHA-treated groups, and it was corroborated by histologic
findings showing decreased ECM deposit and collagen
deposition. Several lines of evidence suggest that histone
acetylation plays a role in transcriptional regulation, probably
by altering chromatin structures. Chromatin fractions enriched
in actively transcribed genes are also enriched in the more
highly acetylated isoforms of the core histones. Suberoylanilide
hydroxamic acid binds directly to the catalytic site of HDAC,
inhibiting its deacetylase enzymatic activity.34 Histone deace-
tylase inhibitors are an emerging group of drugs that can
potentially regulate gene expression by altering the acetylation
of chromatin and other nonhistone proteins.17,18 Initially
developed as anticancer drugs, they are increasingly being
shown to be effective in treating fibrosis.35,36 To our
knowledge, this is the first study to demonstrate the beneficial
effect of an HDACi on the outcome of GFS. Although the exact
mechanism of their antifibrotic effect is not fully understood,
several hypothesis have been proposed, including the sup-
pression of profibrotic genes such as CTGF or upregulation of
antifibrotic genes such as TGIFs and SMAD7.37–39 Additionally,
HDACis have been shown to inhibit proinflammatory cytokine
production and have an anti-inflammatory effect in the disease
FIGURE 7. Suberoylanilide hydroxamic acid treatment decreases F-actin assembly. Representative images showing immunofluorescence staining for
F-actin (marker for activated fibroblasts and myofibroblast) in no-treatment control (A) and SAHA-treated (B) and MMC-treated (C) rabbit ocular
tissue sections. The tissues were collected at day 14 after the glaucoma filtration surgery. Nuclei are stained blue and F-actin is stained red (arrows).
Scale bar: 200 lm. Graph (D) shows a significant (*P < 0.01) decrease in the F-actin–stained area in the SAHA- and MMC-treated rabbit tissues.
Arrowhead shows discontinuous and highly sparse DAPI nuclear staining of the conjunctival epithelium in the MMC-treated rabbit tissue sections.
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models of inflammatory bowel diseases, multiple sclerosis, and
systemic lupus erythematosus.40–43 All of these biologic effects
of HDACis may have collectively contributed to the observed
antifibrotic effect of SAHA in the present study. At present, four
HDACis are being tested in clinical trials. However, SAHA was
selected for this study because it is the only FDA-approved
HDACi in clinical use.
Wound healing is a well-orchestrated event that involves
local and recruited progenitor and differentiated cells, growth
factors and cytokines, ECM, and relevant enzymes that modify
molecular components of the matrix.44 Due to the high
metabolic activity at the wound site, there is an increasing
demand for oxygen and nutrients. Angiogenesis is crucial for
wound healing, which supports new tissue growth by allowing
adequate distribution of oxygen and nutrients for new tissues
to sustain its metabolic needs. It progressively proceeds by
sprouting and elongating new capillaries from the blood
vessels of the intact tissues around the wound. Fibroblasts
are attracted into the wounds and within the wound bed, to
produce collagen as well as glycosaminoglycans and proteo-
glycans, which are major components of the ECM. Following
robust proliferation and ECM synthesis, wound healing should
stop when a tissue gap is filled. In addition, regression of many
of the newly formed capillaries occurs so that vascular density
of the wound returns to normal. In some cases, proliferation
proceeds longer than needed, leading to elevated scars or even
scars whose tissue tends to overgrow. The fibroblast is
considered the pivotal cell in pathologic scarring because of
its role in matrix deposition and remodeling, and HDACi
showed suppression of neovascularization through alteration
of genes directly involved in angiogenesis.45
Wound healing after GFS involves activation and migration
of conjunctival and tenon’s capsule fibroblasts to the
sclerostomy site, followed by their differentiation into myofi-
broblasts.4–7,16,17 Myofibroblasts are highly contractile and
metabolically active cells, causing wound closure by direct
contraction and excessive ECM deposition. In the present
study, SAHA-treated eyes showed significantly less staining for
activated fibroblasts and myofibroblasts in the sclera and
conjunctiva surrounding the surgery site. These observations
suggest that SAHA attenuates post GFS scarring, possibly
through inhibition of fibroblast migration and activation as well
as attenuation of myofibroblast formation. These results are
supported by the previous studies from our lab showing that
SAHA is capable of inhibiting differentiation of cultured rabbit,
equine, canine, and human corneal fibroblasts to myofibro-
blasts.30–32 Furthermore, in the earlier studies a 50-lM or
higher dose of SAHA did not decrease cellular viability of
cultured corneal fibroblasts.30 Therefore, we speculate that in
the present study SAHA did not cause any cytotoxicity to tenon
or conjunctival fibroblasts. Lack of inflammation, corneal
edema, opacity, endophthalmitis, or cataract formation in
SAHA-treated rabbit eyes supports this assumption as well.
Studies are underway to test the effect of SAHA on cultured
tenon and conjunctival fibroblasts. The lack of cytotoxic effect
of SAHA is in stark contrast to currently used drugs MMC or 5-
fluorouracil, which presumably inhibit GFS by causing
myofibroblast cell death. The nonselective cytotoxic effect of
these drugs accounts for the potentially sight-threatening side
effects,11–15 whereas SAHA appears to inhibit myofibroblast
formation while preserving cell viability.
FIGURE 8. Suberoylanilide hydroxamic acid reduces myofibroblast conversion at the site of GFS. Representative images of rabbit ocular tissue
sections of the site of sclerotomy showing immunofluorescence staining for aSMA (a myofibroblast marker) in no-treatment control (A), SAHA-
treated (B), and MMC-treated (C). Nuclei are stained blue, and aSMA is stained green (arrows). Scale bar: 200 lm. Graph (D) shows a significant (*P
< 0.01) decrease in the aSMA-stained area in the SAHA- and MMC-treated rabbit tissues. Arrowhead shows discontinuous and highly sparse DAPI
nuclear staining of the conjunctival epithelium in the MMC-treated rabbit tissue sections.
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Route of administration, application frequency, and dosage
are the three critical determinants of drug efficacy. Previous
studies have shown that drug application before sclerostomy
minimizes drug spillage into the anterior chamber, which
translates to less ciliary body toxicity.46 Therefore, we
preferred to choose preoperative subconjunctival application
of SAHA instead of intraoperative topical application. A one-
time intraoperative application of either MMC or 5-fluorouracil
during GFS is standard practice in clinical setting.8–10 In this
study, our decision to administer one SAHA application was
tailored to reflect this current clinical practice. Suberoylanilide
hydroxamic acid has a short plasma half-life, but based on the
data at hand, one-time SAHA application seems potent enough
to improve GFS outcome. There is no simple and apparent
explanation for these observations. Surgical trauma unfolds a
cascade of interrelated events leading to a vicious cycle of
excessive wound healing. It is possible that a single SAHA
application potently inhibits these early events and can block
the entire fibrotic cascade. Alternatively, SAHA may have some
local tissue binding to show an extended release profile. It is
also possible that the gene transcription changes induced by a
single SAHA dose may last for a few days, which can counter
the ongoing fibrotic process. Finally, we acknowledge the few
limitations of this study. The present study was terminated at
14 days because wound healing in the rabbit model of GFS is
aggressive and leads to bleb failure within 7 to 10 days in
untreated animals. However, longer duration and repeat dose
studies may be required for the future bench-to-bedside
translation of SAHA. Secondly, there was a trend toward lower
IOPs in the SAHA-treated groups, but the results were not
statistically significant. Intraocular pressure is not considered a
reliable indicator in the rabbit model because of the partial
wound closure by the aggressive wound healing.47 Also,
preoperative IOP values are normal in this model, and any
further decrease in IOP is neutralized by a physiologic counter-
regulatory mechanisms. In summary, this study demonstrates
that HDAC inhibition is an attractive pharmacologic target to
modulate GFS wound healing, and SAHA, an HDACi, can be a
useful adjunct to improve the GFS outcome.
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